Granisetron B Braun (Granisetron)

Granisetron B Braun is indicated for the prevention of nausea and vomiting associated with specific medical procedures and treatments. It is commonly employed in the following clinical situations:

• Prevention of chemotherapy‑induced nausea and vomiting (CINV).
• Prevention of postoperative nausea and vomiting (PONV).
• Use as part of anti‑emetic regimens for patients receiving highly emetogenic cancer therapies.
• Adjunct therapy in patients at high risk for nausea after surgery.
• Management of nausea in patients undergoing radiotherapy when indicated by a clinician.

Granisetron B Braun may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require medical attention.

Common

• Headache
• Constipation
• Fatigue
• Dizziness
• Diarrhea
• Injection site discomfort

Serious

• Cardiac arrhythmias (rare)
• Severe allergic reactions such as anaphylaxis
• QT interval prolongation
• Severe hypotension

Before using Granisetron B Braun, certain precautions should be considered to ensure safe administration. Healthcare providers should evaluate the following:

• Patient's cardiac history, especially any prior arrhythmias or prolonged QT interval.
• Concomitant use of other drugs that affect cardiac conduction.
• Renal or hepatic impairment, which may alter drug clearance.
• Pregnancy and lactation status, as safety data are limited.
• Potential for hypersensitivity reactions; discontinue if signs of allergy appear.
• Ensure proper intravenous technique to minimize injection‑site complications.

Granisetron B Braun can interact with other medications, influencing its efficacy or safety profile. Interactions are categorized as follows:

Avoid

• Other QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics).
• Strong CYP3A4 inhibitors that may increase granisetron levels.

Use with caution

• Drugs that also affect serotonin pathways (e.g., SSRIs, SNRIs) due to additive effects.
• Anticholinergic medications that may exacerbate constipation.
• Other antiemetics that may increase the risk of cardiac side effects when combined.
• Medications metabolized by the same hepatic pathways, requiring monitoring.